SOHM Inc (SHMN)

[ChartTRACKER]

$SHMN: I can't repeat this ENOUGH...

Company needs to up the Marketing Ante on their peer reviewed results..
Genentech spent ~3Billion on AVASTIN [one of the use cases was for Wet AMD].
They also got sued B/C AVASTIN performed horribly in breast cancer for women.

All of the above was W/O the ability nor benefit of gene-Editing nor feedback from reading back edited DNA via NextGEN Seq.

There are companies out there that will THROW $100's of Millions, now that CRISPR is FDA approved.
No more MoUs & LOIs etc...ask for Investment & Committed POs.
Have a Good Weekend.

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174227148